Search
Novocure Ltd
NVCRAdd to Watchlist
15.440USD
+0.240+1.58%
Market hours 10/06, 10:04（ET）
1.80BMarket Cap
LossP/E TTM
Novocure Ltd (NVCR) Stock Price Target & Forecast
Analyst Rating
Based on 7 analysts giving stock ratings to Novocure Ltd in the past month.
Buy
1 Strong Buy
3 Buy
3 Hold
0 Sell
0 Strong Sell
Target Price
28.833USD+92.99%
NVCR Analyst Recommendation Trends
In the current month, NVCR has received 3 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. NVCR average Analyst price target in the last month is 28.833.
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
1
1
1
2
2
2
2
2
3
3
3
3
3
3
3
3
3
3
3
2
2
2
2
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7
7
7
7
7
7
7
7
NVCR Analyst Rating for Peer Comparison
Updated: Oct 5, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Medtronic PLC
MDT
8
11
10
0
0
29
Dexcom Inc
DXCM
13
12
4
0
0
29
Stryker Corp
SYK
11
13
5
0
0
29
Abbott Laboratories
ABT
11
13
4
0
0
28
Medline Ord Shs Class A
MDLN
10
12
6
0
0
28
Zimmer Biomet Holdings Inc
ZBH
2
6
20
0
0
28
Insulet Corp
PODD
10
12
5
0
0
27
Guardant Health Inc
GH
12
13
2
0
0
27
Tandem Diabetes Care Inc
TNDM
5
8
10
0
0
23
Repligen Corp
RGEN
5
14
3
0
0
22
Financial Forecasting
Based on analysts' estimates, NVCR EPS is projected to reach -0.244 in FY2026Q3, following reported EPS of -0.135 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.41
-0.51
-0.33
-0.24
-0.25
Actual
-0.22
-0.62
-0.13
--
--
Surprise
+46.89%
-21.51%
+59.29%
--
--
FAQs
What is Novocure Ltd's expected revenue for the next quarter?
Novocure Ltd's expected revenue is 182.23M.
What is Novocure Ltd's price target?
Analysts forecast that Novocure Ltd's price target is USD 28.83, with the highest forecast at USD 52.00 and the lowest forecast at USD 20.00.
How have Novocure LtdNVCR's recent earnings per share performed?
The market expectation was USD -0.13, while Novocure LtdNVCR's earnings per share (EPS) for the previous quarter was USD -0.62. EPS for the next quarter is expected at USD -0.24.
What is the analyst rating for Novocure Ltd?
Based on the ratings of Novocure Ltd's stock from 7 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.